Igor Nastas, MD
Department of Psychiatry, Narcology and Medical Psychology, State University of Medicine and Pharmacy Nicolae Testemitanu, Chișinău, Moldova
Original Research
Add-on Pramipexole for Schizophrenia
August 1, 2022
Several small clinical trials have reported that the dopamine agonist pramipexole was beneficial in treating patients with schizophrenia. This 16-week, multicenter, double-blind, randomized, placebo-controlled study was conducted to test...
